Document:

Exhibit
10.3

 

LIMITED
CONSENT TO

Second
Amended and Restated Note Purchase Agreement

 

THIS
LIMITED CONSENT TO THE Second Amended and Restated Note Purchase Agreement (this “Limited
Consent”) is effectively dated as of the 28th day of September 2022, by and among Staffing 360 Solutions, Inc. (the “Company”)
and Jackson Investment Group, LLC (“Jackson”).

 

RECITALS

 

A. The
Company and Jackson are party to that certain Second Amended and Restated Note Purchase Agreement (the “Note Purchase Agreement”)
and Amended and Restated Senior Secured 12% Promissory Note (the “Jackson Note”) dated as of October 26, 2020
(as amended, amended and restated, supplemented or otherwise modified from time to time) by and among Jackson, the Company, and certain
subsidiaries of the Company signatory thereto. Capitalized terms used in this Limited Consent and not otherwise defined shall have the
meaning ascribed to such terms in the Note Purchase Agreement.

 

B. Prior
to the effectiveness of this Limited Consent, the Jackson Note has a Maturity Date of September 30, 2022 (the “Existing Maturity
Date”).

 

C. Pursuant
to the terms of this Limited Consent, the Company and Jackson intend to extend the Existing Maturity Date to October 14, 2022.

 

CONSENTS

 

NOW,
THEREFORE, in consideration of the foregoing, the terms and conditions set forth in this Limited Consent, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Jackson hereby agree as follows:

 

1. Extension
of Existing Maturity Date. Pursuant to this Limited Consent, the Existing Maturity Date set forth in the Jackson Note, in each instance,
shall be deleted and replaced with October 14, 2022. In addition, each reference (if any) to the Existing Maturity Date set forth in
the Note Purchase Agreement and each other agreement executed in connection therewith shall also be amended to October 14, 2022.

 

2. Confirmation
of Representations and Warranties; Reaffirmation of Security Interest. 

 

(a) Each
Obligor hereby confirms that all of the representations and warranties set forth in Note Purchase Agreement are true and correct in all
material respects with respect to such Borrower as of the date hereof, except to the extent such representations and warranties specifically
relate to an earlier date, and covenants to perform its respective obligations under the Note Purchase Agreement. To induce Jackson to
enter into this Limited Consent, the Obligors represent and warrant that:

 

 (i) no Default or Event of Default has occurred or is continuing as of the date hereof;

 

    	 

     

    

 

(ii) as
of the date hereof and, immediately after giving effect to this Limited Consent and the transactions contemplated hereby, the representations
and warranties of the Obligors contained in the Note Purchase Agreement, the Jackson Note, or any other documents, instruments and agreements
executed or delivered in connection with any of the foregoing are true and correct in all material respects (or if any representation
or warranty is qualified with respect to materiality, in all respects) on and as of the date hereof to the same extent as though made
on and as of such date except to the extent such representations and warranties specifically relate to an earlier date; and

 

(iii) the
execution, delivery and performance by the Obligors of this Limited Consent are within each of its corporate powers and have been duly
authorized by all necessary corporate action, and this Limited Consent is the legal, valid and binding obligation of the Obligors, enforceable
against the Obligors in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency or other similar
laws relating to the enforcement of creditors’ rights generally and by equitable principles, and neither the execution, delivery
or performance by the Obligors of this Limited Consent (A) violates any law, or any other rule or decree of any Governmental Authority,
(B) conflicts with or results in the breach or termination of, constitutes a default under or accelerates any performance required by,
any indenture, mortgage, deed of trust, lease, agreement or other instrument to which the Obligors or the Company is a party or by which
the Obligors or the Company or any of its property is bound, except for such conflicts, breaches, terminations, defaults or accelerations
that would not reasonably be expected to have a Material Adverse Effect, (C) results in the creation or imposition of any Lien upon any
of the Collateral, (D) violates or conflicts with the by-laws or other organizational documents of the Obligors, or (E) requires the
consent, approval or authorization of, or declaration or filing with, any other Person, except for those already duly obtained.

 

(b) Each
Obligor confirms and agrees that all security interests and Liens granted to Jackson continue in full force and effect, and all Collateral
remains free and clear of any Liens, other than those granted to Jackson and Permitted Liens. Nothing herein is intended to impair or
limit the validity, priority or extent of Agent’s security interests in and Liens on the Collateral. For the avoidance of any doubt,
the Collateral secures repayment of the Obligations, and in furtherance thereof, the Obligors hereby reaffirm the grant to Jackson, for
the benefit of itself, of a continuing first priority Lien (subject to Permitted Liens) on and security interest in all of the Collateral
as security for the payment and performance of the Obligations, and for the payment and performance of all obligations under the Note
Purchase Agreement, the Jackson Note, or any other documents, instruments and agreements executed or delivered in connection with any
of the foregoing.

 

3. Enforceability.
This Limited Consent constitutes the legal, valid and binding obligation of each Obligor, and is enforceable against each Obligor
in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws relating
to the enforcement of creditors’ rights generally and by general equitable principles.

 

4. Reaffirmation
of Security Interest. Each of the Obligors confirms and agrees that: (i) all security interests and liens granted to Jackson continue
in full force and effect, and (ii) all Collateral remains free and clear of any liens other than liens in favor of Jackson and Permitted
Liens. Nothing herein contained is intended to impair or limit the validity, priority and extent of Jackson’s security interest
in and liens upon the Collateral.

 

    	 

     

    

 

5. Release.
Each Obligor, voluntarily, knowingly, unconditionally and irrevocably, with specific and express intent, for and on behalf of itself
and all of its respective parents, subsidiaries, affiliates, members, managers, predecessors, successors, and assigns, and each of their
respective current and former directors, officers, shareholders, agents, and employees (collectively, “Releasing Parties”),
does hereby fully and completely release, acquit and forever discharge Jackson of and from any and all actions, causes of action, suits,
debts, disputes, damages, claims, obligations, liabilities, costs, expenses and demands of any kind whatsoever, at law or in equity,
whether matured or unmatured, liquidated or unliquidated, vested or contingent, choate or inchoate, known or unknown that the Releasing
Parties (or any of them) has against the Indemnitees (or any of them), that directly or indirectly arise out of, are based upon or are
in any manner connected with any Prior Related Event. “Prior Related Event” means any transaction, event, circumstance, action,
failure to act, occurrence of any type or sort, whether known or unknown, which occurred, existed, was taken, was permitted or begun
in accordance with, pursuant to or by virtue of (a) any of the terms of this Limited Consent, the Note Purchase Agreement, the Jackson
Note, the Note or any other documents, instruments and agreements executed or delivered in connection with any of the foregoing, (b)
any actions, transactions, matters or circumstances related hereto or thereto, (c) the conduct of the relationship between Jackson and
any Obligor or the Company, or (d) any other actions or inactions by Jackson, all on or prior to the date of this Limited Consent. Each
Obligor acknowledges that the foregoing release is a material inducement to Jackson’s decision to enter into this Limited Consent
and to agree to the modifications contemplated hereunder.

 

6. No
Waiver or Novation. The execution, delivery and effectiveness of this Limited Consent shall not operate as a waiver of any right,
power or remedy of Jackson, nor constitute a waiver of any provision of the Note Purchase Agreement, the Jackson Note, or any other documents,
instruments and agreements executed or delivered in connection with any of the foregoing, except as set forth above. Nothing herein is
intended or shall be construed as a waiver of any existing Defaults or Events of Default under the Note Purchase Agreement, the Jackson
Note or any other documents, instruments and agreements executed or delivered in connection with any of the foregoing or any of Jackson’s
rights and remedies in respect of such Defaults or Events of Default. This Limited Consent (together with any other document executed
in connection herewith) is not intended to be, nor shall it be construed as, a novation of the Note Purchase Agreement or the Jackson
Note or any other documents, instruments and agreements executed or delivered in connection with any of the foregoing.

 

7. Affirmation.
Except as specifically amended pursuant to the terms hereof, the Note Purchase Agreement, the Jackson Note, or any other documents,
instruments and agreements executed or delivered in connection with any of the foregoing (and all covenants, terms, conditions and agreements
therein) shall remain in full force and effect, and are hereby ratified and confirmed in all respects by the Obligors. Each Obligor covenants
and agrees to comply with all of the terms, covenants and conditions of the Note Purchase Agreement, the Jackson Note, or any other documents,
instruments and agreements executed or delivered in connection with any of the foregoing, notwithstanding any prior course of conduct,
waivers, releases or other actions or inactions on Jackson’s part which might otherwise constitute or be construed as a waiver
of or amendment to such terms, covenants and conditions.

 

[Signature
Page Follows]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Limited Consent to be executed by their authorized officers or members, as the case
may be, all as of the day and year first above written.

 

	 	COMPANY:
	 	 
	 	STAFFING 360 SOLUTIONS, INC.
	 	 	 
	 	By:	/s/
    Brendan Flood
	 	Name:	Brendan
    Flood
	 	Title:	Chairman
    and Chief Executive Officer
	 	 	 
	 	SUBSIDIARY GUARANTORS:
	 	 	 
	 	FARO RECRUITMENT AMERICA, INC.
	 	 	 
	 	By:	/s/
    Brendan Flood
	 	Name:	Brendan
    Flood
	 	Title:	Chairman
    and Chief Executive Officer
	 	 	 
	 	MONROE STAFFING SERVICES, LLC
	 	 	 
	 	By:	/s/
    Brendan Flood
	 	Name:	Brendan
    Flood
	 	Title:	Chairman
    and Chief Executive Officer
	 	 	 
	 	KEY RESOURCES, INC.
	 	 	 
	 	By:	/s/
    Brendan Flood
	 	Name:	Brendan
    Flood
	 	Title:	Chairman
    and Chief Executive Officer

 

    	 

     

    

 

	 	 	LIGHTHOUSE
    PLACEMENT SERVICES, INC.
	 	 	 	 
	 	 	By:	/s/
    Brendan Flood
	 	 	Name:	Brendan
    Flood
	 	 	Title:	Chairman
    and Chief Executive Officer
	 	 	 	 
	JACKSON
    INVESTMENT GROUP, LLC 	 	 
	 	 	 	 
	By:	/s/
    Richard L. Jackson	 	 
	Name:	Richard
    L. Jackson	 	 
	Title:	Chief
    Executive OfficerExhibit
4.13

 

CURATIVE
BIOTECHNOLOGY, INC.

 

NOTICE
OF GRANT

 

You
have been granted a Nonstatutory Stock Option to purchase Common Stock of the Company, subject to the terms and conditions of this agreement,
as follows:

 

Name
of Optionee: Sohn Health Strategies LLC

 

Date
of Grant: September 27, 2021

 

Vesting
Commencement Date: September 27, 2021

 

Exercise
Price per Share: $0.11

 

Total
Number of Shares Granted: 8,081,037, subject to adjustment as set forth in Section 10(d) of this Agreement.

 

Total
Exercise Price: $888,914.07

 

Term/Expiration
Date: September 27, 2031

 

Vesting
Schedule: the Options vest (i) 50% on September 27, 2021 and (ii) 50% on September 27, 2022.

 

I.
TERMS

 

This
Option shall vest and may be exercised, in whole or in part, in accordance with the Vesting Schedule set forth above after the Vesting
Commencement Date, subject to the Optionee continuing to be a Service Provider on such date. This Option may be exercised for three (3)
months after Optionee ceases to be a Service Provider in accordance with Section 8 of this Agreement. Upon the death or Disability of
the Optionee, this Option may be exercised for three (3) months after the Optionee ceases to be a Service Provider in accordance with
Sections 9 and 10 of this Agreement. In no event shall this Option be exercised later than the Term/Expiration Date provided.

 

II.
AGREEMENT

 

1.
Definitions..— As used herein, the following terms shall have the following meanings:

 

(a)
“Agreement” means this Stock Option Agreement between the Company and Optionee evidencing the terms and conditions of this
Option.

 

(b)
“Applicable Laws” means the requirements relating to the administration of stock Options under U.S. state corporate laws,
U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted
and the applicable laws of any foreign country or jurisdiction that may apply to this Option.

 

(c)
“Board” means the Board of Directors of the Company or any committee of the Board that has been designated by the Board to
administer this Agreement.

 

(d)
“Capital Raising Event” has the meaning set forth in Section 10(d) hereof.

 

(e)
“Code” means the Internal Revenue Code of 1986, as amended.

 

(f)
“Common Stock” means the common stock, $0.0001 par value of the Company.

 

(g)
“Company” means Curative Biotechnology, Inc., a Florida corporation.

 

(h)
“Consultant” means any person, including an advisor, engaged by the Company or a Parent or Subsidiary to render services
to such entity.

 

(i)
“Director” means a member of the Board.

 

(j)
“Disability” means total and permanent disability as defined in Section 22(e)(3) of the Code.

 

(k)
“Employee” means any person, including Officers and Directors, employed by the Company or any Parent or Subsidiary of the
Company. A Service Provider shall not cease to be an Employee in the case of (i) any leave of absence approved by the Company or (ii)
transfers between locations of the Company or between the Company, its Parent, any Subsidiary, or any successor. Neither service as a
Director nor payment of a director’s fee by the Company shall be sufficient to constitute “employment” by the Company.

 

    	 

    	 

    

 

(l)
“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

(m)
“Fair Market Value” means, as of any date, the value of Common Stock determined as follows:

 

(1)
If the Common Stock is listed on any established stock exchange or a national market system, including without limitation the New York
Stock Exchange or The NYSE American, Nasdaq, Nasdaq Capital Market, Nasdaq Global Select Market, or Over the Counter Bulletin Board,
its Fair Market Value shall be the closing sales price for such stock (or the closing bid price, if no sales were reported) as quoted
on such exchange or system on the day of determination, as reported in The Wall Street Journal or such other source as the Board deems
reliable;

 

(2)
If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, its Fair Market Value
shall be the mean the average of the high bid and low asked prices for the Common Stock on the day of determination; or

 

(3)
In the absence of an established market for the Common Stock, the Fair Market Value shall be determined in good faith by the Board.

 

(n)
“Nonstatutory Stock Option” means an Option not intended to qualify as an incentive stock Option within the meaning of Section
22 of the Code and the regulations promulgated thereunder.

 

(o)
“Notice of Grant” means a written notice, prior to Section 1 of this Agreement, evidencing certain terms and conditions of
this Option grant. The Notice of Grant is part of the Option Agreement.

 

(p)
“Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules
and regulations promulgated thereunder.

 

(q)
“Option” means this stock Option.

 

(r)
“Optioned Stock” means the Common Stock subject to this Option.

 

(s)
“Optionee” means the person named in the Notice of Grant of such person’s successor.

 

(t)
“Parent” means a “parent corporation,” whether now or hereafter existing, as defined in Section 24(e) of the
Code.

 

(u)
“Service Provider” means an Employee, Director or Consultant.

 

(v)
“Share” means a share of the Common Stock, as adjusted in accordance with Section 11 of this Agreement.

 

(w)
“Subsidiary” means a “subsidiary corporation,” whether now or hereafter existing, as defined in Section 24(f)
of the Code.

 

    	 

    	 

    

 

2.
Grant of Option. — The Board hereby grants to the Optionee named in the Notice of Grant attached to the Agreement, the
Option to purchase the number of Shares, as set forth in the Notice of Grant, at the exercise price per share set forth in the Notice
of Grant (the “Exercise Price”), subject to the terms and conditions of this Agreement.

 

3.
Exercise of Option. —

 

(a)
Right to Exercise. This Option is exercisable during its term in accordance with the Vesting Schedule set out in the Notice of Grant
and the applicable provisions of this Agreement.

 

(b)
Method of Exercise. This Option is exercisable by delivery of an exercise notice, in the form attached as Exhibit A (the “Exercise
Notice”), which shall state the election to exercise the Option, the number of Shares in respect of which the Option is being exercised
(the “Exercised Shares”), and such other representations and agreements as may be required by the Company. The Exercise Notice
shall be completed by the Optionee and delivered to the Secretary of the Company. The Exercise Notice shall be accompanied by payment
of the aggregate Exercise Price as to all Exercised Shares. This Option shall be deemed to be exercised upon receipt by the Company of
such fully executed Exercise Notice accompanied by such aggregate Exercise Price.

 

(c)
Legal Compliance. No Shares shall be issued pursuant to the exercise of this Option unless such issuance and exercise complies with Applicable
Laws. Assuming such compliance, for income tax purposes the Exercised Shares shall be considered transferred to the Optionee on the date
the Option is exercised with respect to such Exercised Shares.

 

4.
Method of Payment. — Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof,
at the election of the Optionee:

 

(a)
cash or check;

 

(b)
consideration received by the Company under a cashless exercise program implemented by the Company; or

 

(c)
surrender of other Shares, provided such Shares were acquired directly from the Company, (i) have been owned by the Optionee for more
than twelve (12) months on the date of surrender, and (ii) have a Fair Market Value on the date of surrender equal to the aggregate Exercise
Price of the Exercised Shares.

 

5.
Non-Transferability of Option. — This Option may not be transferred in any manner otherwise than by will or by the laws
of descent or distribution and may be exercised during the lifetime of Optionee only by the Optionee. The terms of this Agreement shall
be binding upon the executors, administrators, heirs, successors and assigns of the Optionee.

 

6.
Term of Option. — This Option may be exercised only within the term set out in the Notice of Grant, and may be exercised
during such term only in accordance with the terms of this Agreement.

 

7.
Termination of Relationship as a Service Provider..— If the Optionee ceases to be a Service Provider (other than for
death or Disability), this Option may be exercised for a period of three (3) months after the date of such termination (but in no event
later than the term/expiration date of this Option as set forth in the Notice of Grant) to the extent that the Option is vested on the
data of such termination. To the extent that the Optionee does not exercise this Option within the time specified herein, the Option
shall terminate.

 

8.
Disability of Optionee. — If the Optionee ceases to be a Service Provider as a result of the Optionee’s Disability,
this Option may be exercised for a period of three (3) months after the date of such termination (but in no event later than the expiration
date of this Option as set forth in the Notice of Grant) to the extent that the Option is vested on the date of such termination. To
the extent that Optionee does not exercise this Option within the time specified herein, the Option shall terminate.

 

9.
Death of Optionee. — If the Optionee dies while a Service Provider, the Option may be exercised at any time within three
(3) months following the date of death (but in no event later than the expiration date of this Option as set forth in the Notice of Grant),
by the Optionee’s estate or by a person who acquired the right to exercise the Option by bequest or inheritance, but only to the extent
that the Optionee was entitled to exercise the Option at the date of death. If, after death, the Optionee’s estate or a person who acquired
the right to exercise the Option by bequest or inheritance does not exercise the Option within the time specified herein, the Option
shall terminate.

 

10.
Adjustments upon Changes in Capitalization, Dissolution, Merger or Asset Sale. —

 

(a)
Changes in Capitalization. Subject to any required action by the stockholders of the Company, the number of shares of Common Stock covered
by this Option, as well as the price per share of Common Stock covered by this Option, shall be proportionately adjusted for any increase
or decrease in the number of issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination
or reclassification of the Common Stock, or any other increase or decrease in the number of issued shares of Common Stock effected without
receipt of consideration by the Company; provided, however, that conversion of any convertible securities of the Company shall not be
deemed to have been “effected without receipt of consideration.” Such adjustment shall be made by the Board, whose determination
in that respect shall be final, binding and conclusive. Except as expressly provided in this Agreement, no issuance by the Company of
shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason
thereof shall be made with respect to, the number or price of shares of Common Stock subject to this Option.

 

    	 

    	 

    

 

(b)
Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the Board shall notify Optionee as
soon as practicable prior to the effective date of such proposed transaction. The Board in its discretion may provide for the Optionee
to have the right to exercise his or her Option until fifteen (15) days prior to such transaction as to all of the Optioned Stock covered
thereby, including Shares as to which the Option would not otherwise be exercisable. To the extent it has not been previously exercised,
the Option will terminate immediately prior to the consummation of such proposed.

 

(c)
Merger or Asset Sale. In the event of a merger of the Company with or into another corporation, or the sale of substantially all of the
assets of the Company, the Option shall be assumed or an equivalent Option substituted by the successor corporation or a Parent or Subsidiary
of the successor corporation. In the event that the successor corporation refuses to assume or substitute for the Option, the Optionee
shall fully vest in and have the right to exercise the Option as to all of the Optioned Stock, including Shares as to which it would
not otherwise be vested or exercisable. If the Option becomes fully vested and exercisable in lieu of assumption or substitution in the
event of a merger or sale of assets, the Board shall notify the Optionee in writing or electronically that the Option shall be fully
exercisable for a period of fifteen (15) days from the date of such notice, and the Option shall terminate upon the expiration of such
period. For the purposes of this paragraph, the Option shall be considered assumed if, following the merger or sale of assets, the Option
confers the right to purchase or receive, for each Share of Optioned Stock subject to the Option immediately prior to the merger or sale
of assets, the consideration (whether stock, cash, or other securities or property) received in the merger or sale of assets by holders
of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration,
the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration
received in the merger or sale of assets is not solely common stock of the successor corporation or its Parent, the Board may, with the
consent of the successor corporation, provide for the consideration to be received upon the exercise of the Option, for each Share of
Optioned Stock subject to the Option, to be solely common stock of the successor corporation or its Parent equal in fair market value
to the per share consideration received by holders of Common Stock in the merger or sale of assets.

 

(d)
Adjustment on Offering / Reverse Stock Split – In the event that the Company completes a reverse stock split and capital
raising transaction of at least $5,000,000 (collectively, both conditions, the “Capital Raising Event”), then upon the completion
of such Capital Raising Event, the number of Shares underlying the Option (as set forth in the Notice of Grant) will increase such that
the number of Shares underlying the Option will be equal to one percent (1.00%) of the fully diluted capital stock of the Company. Such
adjustment will only occur one (1) time upon the first Capital Raising Event.

 

11.
Notices.— Any notice to be given to the Company hereunder shall be in writing and shall be addressed to the Company
at its then current principal executive office or to such other address as the Company may hereafter designate to the Optionee by notice
as provided in this Section. Any notice to be given to the Optionee hereunder shall be addressed to the Optionee at the address set forth
beneath Optionee’s signature hereto, or at such other address as the Optionee may hereafter designate to the Company by notice
as provided herein. A notice shall be deemed to have been duly given when personally delivered or mailed by registered or certified mail
to the party entitled to receive it.

 

    	 

    	 

    

 

12.
Withholding Taxes. —Optionee agrees to make appropriate arrangements with the Company (or the Parent or Subsidiary employing
or retaining Optionee) for the satisfaction of all Federal, state, and local income and employment tax withholding requirements applicable
to the Option exercise. Optionee acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver Shares
if such withholding amounts are not delivered at the time of exercise.

 

13.
Entire Agreement; Governing Law. —This Agreement constitutes the entire agreement of the parties with respect to the
subject matter hereof and supersedes in its entirety all prior undertakings and agreements of the Company and Optionee with respect to
the subject matter hereof, and may not be modified adversely to the Optionee’s interest except by means of a writing signed by the Company
and Optionee. This agreement is governed by the internal substantive laws, but not the choice of law rules, of Florida

 

14.
No Guarantee of Continued Service. —Optionee acknowledges and agrees that the vesting of shares pursuant to the vesting
schedule hereof is earned only by continuing as a Service Provider at the will of the Company (and not through the act of being hired,
being granted an Option or purchasing Shares hereunder). Optionee further acknowledges and agrees that this Agreement, the transactions
contemplated hereunder and the vesting schedule set forth herein do not constitute an express or implied promise of continued engagement
as a Service Provider for the vesting period, for any period, or at all, and shall not interfere with Optionee’s right or the Company’s
right to terminate Optionee’s relationship as a service provider at any time, with or without cause.

 

	OPTIONEE	 	Curative
    Biotechnologies, Inc.
	 	 	 
	/s/
    Sohn Health Strategies LLC	 	/s/
    Richard Garr
	By: 	Catherine Sohn	 	By: 	Richard Garr                          
	Its: 	Manager	 	Its: 	CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]